Cochrane · systematic review · CD012838
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review
Narayan, V, Kahlmeyer, A, Dahm, P, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 2 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Pembrolizumab compared to chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to death from any cause (here: overall mortality at 12‐month Pembrolizumab vs chemotherapy | HR 0.73 [0.59, 0.9] | 1 study · 542 participants | Moderate Downgraded: imprecision |
Quality of life (Change from baseline to week 15) Pembrolizumab vs chemotherapy | MD 9.05 [4.61, 13.5] | 1 study · 519 participants | Low Downgraded: risk of bias, imprecision |
Response rate (partial and complete response) Pembrolizumab vs chemotherapy | RR 1.85 [1.24, 2.77] | 1 study · 542 participants | Moderate Downgraded: imprecision |
Treatment‐related mortality Pembrolizumab vs chemotherapy | RR 0.96 [0.24, 3.79] | 1 study · 521 participants | Low Downgraded: imprecision |
Discontinuation due to adverse event Pembrolizumab vs chemotherapy | RR 0.66 [0.39, 1.1] | 1 study · 521 participants | Low Downgraded: imprecision |
Serious adverse events (irrespective of attribution to treatment) Pembrolizumab vs chemotherapy | RR 0.83 [0.72, 0.97] | 1 study · 521 participants | Low Downgraded: imprecision |